Blue Earth expands PSMA-PET/CT imaging portfolio

By staff writers

May 7, 2018 -- Molecular imaging firm Blue Earth Diagnostics has signed an agreement for exclusive rights to radiopharmaceutical technology firm Scintomic's "radiohybrid" prostate-specific membrane antigen (rhPSMA-7) imaging agent.

The rhPSMA-7 imaging compound is capable of targeting and labeling prostate cancer cells in conjunction with either PET imaging radiopharmaceuticals such as Blue Earth's Axumin (fluciclovine F-18) or therapeutic radioisotopes such as lutetium-177 (Lu-177), according to the company. This potentially allows for rhPSMA-7 to facilitate both imaging and therapy for prostate cancer.

Blue Earth plans to continue developing rhPSMA-7 and to collaborate with Scintomics on optimizing its therapeutic applications for prostate cancer therapy.

Copyright © 2018

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking